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Macrophage activation syndrome (MAS) is known to be a severe and potentially life-
threatening complication of rheumatic disorder, especially systemic juvenile rheu-
matoid arthritis. It is very rare for MAS to be an initial presentation of systemic 
lupus erythematosus (SLE). Here, we report a 14-year-old girl in whom MAS devel-
oped as an initial presentation of SLE. With early diagnosis and administration of 
cyclosporine A, she had a fair outcome. Further testing showed positive anti-dsDNA 
about 8 months later.
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1. Case Report
A previously healthy 14-year-old girl was referred 
to our department with 20 days’ history of persistent 
fever (range, 38.5−40°C), mild dry cough, and bilat-
eral neck pain and weight loss. There was no family 
history of rheumatic disease. She also had no past 
history of severe infection or immunodeficiency. 
She exhibited no butterfly rash, mucous membrane 
abnormalities, photosensitivity, arthritis, edema, or 
hepatosplenomegaly.
Physical examination on admission revealed bi-
lateral neck lymphadenopathy (1.5 × 1.5 cm). Labora-
tory examination found leukopenia (white blood cell 
count, 2800/cm3; absolute neutrophil count, 2251/
cm3), thrombocytopenia (75,000/cm3), impair-
ment of liver function (alanine aminotransferase, 
150 U/L; aspartate aminotransferase, 181 U/L), and 
positive antinuclear antibody (1:1280) (speckle). 
Serum antibody test for mycoplasma IgM (equivocal, 
16.70 BU/mL) and IgG (positive, 31.58 BU/mL), 
Epstein-Barr virus anti-VCA IgM (negative) and IgG 
(1:640), cytomegalovirus IgG (negative, 3.5 AU/mL) 
and IgM (negative), herpes simplex virus IgM (nega-
tive) and IgG (positive, 11.843 RU/mL) all showed no 
evidence of recent infection. Findings for comple-
ment C3 (111 mg%), C4 (19.70 mg%), rheumatic fac-
tor (< 11 IU/mL), anti-dsDNA (13.1 IU/mL), anti-Sm 
(3.1 U/mL), anti-SSA (2.4 U/mL), and anti-SSB (1.3 U/
mL) were all negative.
Seven days after admission, the patient developed 
severe epistaxis and status epilepticus. Magnetic 
resonance imaging and electroencephalography both 
showed encephalopathy. Under suspicion of autoim-
mune disease-related encephalopathy, methylpred-
nisolone pulse therapy (1 g/day) was administered 
for 3 consecutive days. However, the patient’s con-
dition did not improve. She then developed profound 
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depression of blood cell lines (white blood cell count, 
2400/cm3; absolute neutrophil count, 1080/cm3; 
hemoglobin, 8.4 g/dL; platelet count, 46,000/cm3), 
prolonged activated partial thromboplastin time 
(> 120 s), hematuria, proteinuria, disseminated intra-
vascular coagulopathy, hyperglycemia, hyperam-
monemia and renal function impairment. Bone 
marrow aspiration revealed increased histiocytes 
with evidence of hemophagocytosis (Figure 1). 
Diagnosis of systemic lupus erythematosus (SLE) 
with macrophage activation syndrome (MAS) was 
supported by high ferritin level (73,968 µg/L), low 
platelet count (89,000/cm3), impaired liver func-
tion (aspartate aminotransferase, 2534 U/L; alanine 
aminotransferase, 375 U/L), low fibrinogen (141 g/L), 
high triglyceride (297 mg/dL), and high lactate de-
hydrogenase (2675 U/L).
The patient was started on intravenous gamma 
globulin (IVIG) infusion, followed by intravenous 
cyclosporine A (5 mg/kg/day). After 7 days of treat-
ment, her condition improved greatly, and oral pred-
nisolone was used as therapy. She has had a fair 
course since then. Further testing showed positive 
anti-dsDNA (321.46 IU/mL) about 8 months later.
2. Discussion
Hemophagocytic lymphohistiocytosis (HLH) is a 
syndrome that is composed of different disease 
entities classified into two groups, genetic and ac-
quired HLH.1 Genetic HLH includes familial HLH and 
immunodeficiency-associated HLH. Acquired HLH 
diseases include infection-associated hemophago-
cytic syndrome (IAHS), MAS associated with rheu-
matic diseases, inborn errors of metabolism and 
malignancy-associated HLH.2 The pathologic findings 
of HLH result from the aggressive proliferation of nor-
mal histiocytes in various tissues. Hemopha gocytosis 
of red cells (erythrophagocytosis), other white blood 
cells or platelets in the bone marrow, spleen or 
lymph nodes is the key diagnostic finding.
The clinical presentations of MAS are sudden 
onset of non-remitting high fever, hepatospleno-
megaly, lymphadenopathy, hemorrhage and central 
nervous system dysfunction. There is usually profound 
depression of all three blood cell lines, elevation of 
serum liver enzymes, abnormal coagulation profile 
with hypofibrinogenemia and hypertriglyceridemia. 
The important laboratory hallmark of MAS is hyper-
ferritinemia. Results from the HLH-94 study indi-
cated that a ferritin level ≥ 500 µg/L was 80% specific 
for the diagnosis. Numerous well-differentiated mac-
rophages actively phagocytosing hematopoietic cells 
are seen on bone marrow exami nation.3
The widely used criteria for diagnosing MAS are 
the HLH criteria, which include fever, splenomegaly, 
cytopenias affecting at least two of three lineages 
in the peripheral blood, hypertriglyceridemia and/
or hypofibrinogenemia, hemophagocytosis in bone 
marrow, spleen or lymph nodes, low or absent nat-
ural killer cell activity, hyperferritinemia, and high 
levels of sIL-2r (Table 1). Altogether, five of the eight 
criteria must be fulfilled; patients with a molecular 
diagnosis consistent with HLH do not necessarily 
need to fulfill the diagnostic criteria.4−8
MAS was first described as a complication of 
systemic-onset juvenile rheumatoid arthritis in 1985 
by Hadchouel et al.9 MAS has also been observed in a 
small number of patients with many other rheumatic 
disorders: polyarticular juvenile rheumatoid arthri-
tis, SLE, rheumatoid arthritis, sarcoidosis, dermato-
myositis, and Kawasaki disease.10,11
MAS is a rare and potentially fatal complication 
of childhood rheumatic disorders. It is even rarer 
for MAS to be an initial presentation of SLE. Only 
four cases have been reported to date.11−14 Our 
patient is the fifth case to be published in the liter-
ature. Most physicians rely on diagnostic criteria for 
lupus that were developed by the American Rheu-
matism Association (ARA, now the American College 
of Rheumatology or ACR) (Table 2).15,16 The proposed 
classification is based on 11 criteria, including malar 
rash, discoid rash, photosensitivity, oral ulcers, ar-
thritis, serositis, renal disorder, neurologic disorder, 
hematologic disorder, immunologic disorder and an-
tinuclear antibody. The diagnosis of SLE is made if 
four or more of the manifestations are present, either 
serially or simultaneously, during any interval of ob-
servation. However, delayed diagnosis or misdiagno-
sis may occur due to the absence of the typical 
findings of SLE at disease onset. Our patient only 
presented with leukopenia and positive antinuclear 
antibody initially, until complicated with MAS, SLE 
being diagnosed based upon four of the 11 criteria 
(seizure, proteinuria, cytopenia, positive antinuclear 
Figure 1  Smear of bone marrow shows stimulated histio-
cytes phagocytosing platelets and erythroblasts (arrow).
SLE presenting with MAS 41
Table 1  Revised diagnostic guidelines for hemophagocytic lymphohistiocytosis (HLH)
Diagnosis of HLH is established if either one or both of the criteria below are fulfilled.
(1) A molecular diagnosis consistent with HLH
(2) Diagnostic criteria for HLH fulfilled (≥ 5 of the 8 criteria below)
   Fever
   Splenomegaly
   Cytopenias affecting ≥ 2 of 3 lineages in peripheral blood:
    − hemoglobin < 90 g/L (in infants < 4 wk: hemoglobin < 100 g/L)
    − platelets < 100 ˜  109/L
    − neutrophils < 1.0 ˜  109/L
   Hypertriglyceridemia and/or hypofibrinogenemia:
    − fasting triglycerides ≥ 3.0 mmol/L (≥ 265 mg/dL)
    − fibrinogen ≤ 1.5 g/L
   Hemophagocytosis in bone marrow, spleen, lymph nodes or cerebrospinal fluid:
    − no evidence of malignancy
   Low or absent natural killer cell activity (according to local laboratory reference)
   Elevated ferritin (≥ 500 µg/L)
   Soluble CD25 (i.e., soluble interleukin-2 receptor) ≥ 2400 U/mL
Table 2  American Rheumatism Association criteria for the diagnosis of systemic lupus erythematosus (SLE)
Diagnosis of SLE is made if four or more of the manifestations below are present, either serially or simultaneously
during any interval of observation.
 Malar rash  Fixed erythema, flat or raised, over the malar eminence, tending to spare the 
 nasolabial folds
 Discoid rash  Erythematous raised patches with adherent keratotic scaling and follicular plugging;
 atrophic scarring may occur in older lesions
  Photosensitivity  Skin rash as a result of unusual reaction to sunlight, by patient history or physician
 observation
 Oral ulcers Oral or nasopharyngeal ulceration, usually painless, observed by physician
 Arthritis  Nonerosive arthritis involving ≥ 2 peripheral joints, characterized by tenderness,
 swelling or effusion
 Serositis  Pleuritis convincing history of pleuritic pain or rub heard by physician or evidence of 
 pleural effusion OR pericarditis documented by electrocardiography, rub or 
 evidence of pericardial effusion
 Renal disorder  Persistent proteinuria > 0.5 g/day or > 3 + if quantitation not performed OR cellular
 casts may be red cell, hemoglobin, granular, tubular or mixed
 Neurologic disorder  Seizure OR psychosis in the absence of offending drugs or known metabolic 
 derangements (uremia, ketoacidosis or electrolyte imbalance)
 Hematologic disorder Hemolytic anemia with reticulocytosis OR
 Leukopenia < 4000/mm3 total on ≥ 2 occasions
 Lymphopenia < 1500/mm3 on ≥ 2 occasions
 Thrombocytopenia < 100,000/mm3 in the absence of offending drugs
 Immunologic disorder Positive antiphospholipid antibody OR
 Anti-DNA antibody to native DNA in abnormal titer OR
 Anti-Sm presence of antibody to Sm nuclear antigen OR
  False-positive serologic test for syphilis known to be positive for at least 
 6 months and confirmed by Treponema pallidum
 Antinuclear antibody  Abnormal titer of antinuclear antibody by immunofluorescence or an equivalent assay
 at any point in time and in the absence of drugs known to be associated with
 “drug-induced lupus” syndrome
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antibody). We suggest that in the presence of a sig-
nificant titer of antinuclear antibodies, children who 
present acutely with only fever should be considered 
to have an autoimmune disorder. Since the differen-
tiation of an autoimmune disease flare from sepsis 
may be difficult, simultaneous treatment for both 
conditions is required.
Moderate to high titers of anti-dsDNA antibodies 
are very specific for SLE.17 Serial measurement of 
anti-dsDNA is also used as an aid to monitor the 
activity of lupus nephritis. It has been reported that 
85% of the patients who do not have SLE at the time 
high avidity anti-DNA is detected in their serum will 
develop the disease within the next few years. Pa-
tients with only low avidity anti-DNA in their circu-
lation develop a milder form of SLE; the low avidity 
of their anti-DNA seldom increases during the course 
of their disease.17 It is interesting that our case pre-
sented with negative anti-dsDNA initially and had 
progressed to 321.46 IU/mL about 8 months later.
The primary aim of MAS therapy is to suppress 
the hyperinflammatory state. The initial manage-
ment of patients with MAS is usually with adminis-
tration of high doses of corticosteroids.18 Cyclo sporine 
A has also been proven to be effective in treating 
severe or corticosteroid-resistant cases.3 It has been 
reported that intravenous cyclosporine A therapy 
(3−7 mg/kg/day and trough levels between 200 and 
400 ng/mL) during the early stage of the disease 
course will yield a better outcome.14,19 If there is no 
response to this treatment, use of the HLH-2004 
protocol is recommended.8 In a retrospective survey, 
we found that all patients with MAS survived with 
early cyclosporine A treatment.18
In conclusion, although rare, MAS could be an ini-
tial presentation of SLE. A better prognosis can be 
obtained with early diagnosis and prompt adminis-
tration of cyclosporine A.
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